HER2 CAR-NK Cell Therapy for Off-the-Shelf Repeat Dosing
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer treatments using autologous and allogeneic CAR-T cell therapies face challenges such as resource-intensive manufacturing, long wait times, high costs, adverse effects, and inefficacy due to immune system clearance, particularly for HER2-specific cancers, with no approved autologous CAR-T therapies and allogeneic therapies risking graft-versus-host disease and rapid clearance.
Innovation Solution
Allogeneic NK cells engineered to express a HER2-specific chimeric antigen receptor (CAR) can be manufactured in bulk, cryopreserved, and administered on demand, offering repeat dosing and tailored treatment without the need for HLA matching or genetic manipulations, and can be used in combination with traditional antibody therapies.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Loss of time
If allogeneic CAR-T cell therapies are used, then manufacturing time is reduced and cells can be administered immediately, but the risk of graft-versus-host disease increases and cells are rapidly cleared by the patient's immune system
Solution Approach 1:
The patent segments the CAR-T cell population into different subsets (CD4+ and CD8+ T cells) and selectively expands and administers specific subsets that have been engineered to express anti-CD19 CAR and resist host immune rejection through HLA-matching or HLA-deletion strategies
Solution Approach 2:
The patent uses HLA-matched allogeneic T cells as an intermediary solution, where the donor T cells are selected based on HLA compatibility with the recipient to reduce GVHD risk while maintaining the ability to rapidly manufacture and administer off-the-shelf cell products
2Adaptability or versatility
If autologous CAR-T cell therapies are used, then the therapy is tailored to the patient's own immune system, but the manufacturing process is resource-intensive and takes an average of 3 weeks
Solution Approach 1:
The patent performs preliminary actions by pre-screening and selecting HLA-matched donor T cells before patient treatment, creating a bank of ready-to-administer allogeneic CAR-T cell products that can be immediately infused without waiting for autologous cell manufacturing
Solution Approach 2:
The patent inverts the traditional autologous approach by using allogeneic donor T cells instead of patient-derived T cells, thereby eliminating the need for time-consuming patient-specific manufacturing while still achieving effective anti-tumor activity through CAR engineering and HLA-matching
3Reliability
If CAR-T cell products are administered to critically ill patients, then targeted therapy is provided, but the 3-week manufacturing time is too long for these patients
Solution Approach 1:
The patent employs disposable, off-the-shelf allogeneic CAR-T cell products that have a limited shelf life but can be immediately administered to critically ill patients without requiring long-term manufacturing processes, accepting that these pre-manufactured cells will be used and depleted quickly in the patient
4Reliability
If complex CAR-T cell manufacturing and delivery processes are implemented, then effective targeted therapy is achieved, but access becomes out of reach financially and geographically for most patients
Solution Approach 1:
The patent creates universal HLA-matched allogeneic CAR-T cell products that can be manufactured once and administered to multiple patients with similar HLA types, thereby reducing the overall manufacturing burden and making the therapy more accessible to a broader population rather than requiring individualized autologous manufacturing for each patient
5Ease of manufacture
If allogeneic NK cells are used, then HLA matching and genetic manipulations are not required, but the cells must be engineered to express specific CAR receptors
Solution Approach 1:
The patent extracts and isolates the essential anti-tumor function by engineering NK cells to express only the necessary CAR receptor components (single-chain variable fragment and signaling domains) while leaving out the complex HLA matching and genetic manipulations required for T cell therapies, thereby simplifying the manufacturing process
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Allogeneic HER2-specific CAR-NK cells provide a safe and effective treatment option for HER2+ cancers, overcoming manufacturing limitations and adverse effects, enabling immediate administration, repeat dosing, and maintaining a prolonged therapeutic response, even in the presence of downstream signaling mutations.
Implementation Method 1
NK cells engineered to express a HER2-specific chimeric antigen receptor (CAR)
Implementation Method 2
Natural killer cells are cytolytic cells of the innate immune system with an intrinsic ability to lyse tumor cells
Implementation Method 3
Natural killer cells also engage tumor cells through antibody dependent cellular cytotoxicity (ADCC). To initiate ADCC, NK cells engage with antibodies via the CD16 receptor on their surface
Implementation Method 4
Activated NK cells secrete cytokines and chemokines, such as interferon gamma (IFNγ); tumor necrosis factor alpha (TNFα); and macrophage inflammatory protein I (MIPI) that signal and recruit T cells to tumors
Data Source
AI summary
Provided herein, among other things, are methods of administering NK cells comprising poly nucleotides comprising a nucleic acid encoding an anti-human epidermal growth factor receptor 2 (HER2) chimeric antigen receptor (CAR).